Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Employers Eye CER To Improve Employee Health, Lower Costs – NPC Survey

Executive Summary

Large employers and those companies that self-insure are expecting that comparative effectiveness research will lead to better employee health and help companies achieve their cost-management goals, according to the results of a survey released June 21 by the National Pharmaceutical Council.

You may also be interested in...



Physicians Still Concerned PCORI Will Investigate Cost-Effectiveness

Despite a carefully worded statute aimed at keeping cost-effectiveness research out of the work conducted by the Patient-Centered Outcomes Research Institute, the American Medical Association is still concerned that cost could play a role in the institute’s work.

Physicians Still Concerned PCORI Will Investigate Cost-Effectiveness

Despite a carefully worded statute aimed at keeping cost-effectiveness research out of the work conducted by the Patient-Centered Outcomes Research Institute, the American Medical Association is still concerned that cost could play a role in the institute’s work.

Cost Quietly Remains The 800-Pound Gorilla In The CER Room

In the run-up to passage of the Patient Protection and Affordable Care Act, there was much debate on the subject of cost effectiveness in the context of comparative effectiveness research, with legislators carefully wording CER provisions to keep cost effectiveness at bay

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS053567

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel